A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work was to develop a mechanistic whole-body physiologically ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanke, Nina, Türk, Denise, Selzer, Dominik, Wiebe, Sabrina, Fernandez, Éric, Stopfer, Peter, Nock, Valerie, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355632/
https://www.ncbi.nlm.nih.gov/pubmed/32560124
http://dx.doi.org/10.3390/pharmaceutics12060556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355632/
https://www.ncbi.nlm.nih.gov/pubmed/32560124
http://dx.doi.org/10.3390/pharmaceutics12060556

Ejemplares similares